Our Epitope Discovery Platform revealed a more stable, first-in-class MUC-1 epitope in cancers. And it’s already redefining what’s possible for therapeutic antibody development for solid tumors.
Our Epitope Discovery Platform revealed a more stable, first-in-class MUC-1 epitope in cancers. And it’s already redefining what’s possible for therapeutic antibody development for solid tumors.
By binding to a longer, more stable epitope, SANA-01 antibody makes more contacts with an affinity and specificity rarely seen in drug development, creating a precision hand-in-glove fit.
By binding to a longer, more stable epitope, SANA-01 antibody makes more contacts with an affinity and specificity rarely seen in drug development, creating a precision hand-in-glove fit.
Higher affinity and specificity don’t just create new possibilities. They can reduce dosage and potential side effects, helping patients fight cancer faster and more comfortably.
Higher affinity and specificity don’t just create new possibilities. They can reduce dosage and potential side effects, helping patients fight cancer faster and more comfortably.
SANA-01 antibody is designed to help more patients in a broader range of cancers than other MUC-1 antibodies in development today.
SANA-01 antibody is designed to help more patients in a broader range of cancers than other MUC-1 antibodies in development today.